Non Hodgkin ADC collaborations with genentech in heavily pretreated relapsed refractory patients appear to be producing a decent amount of Complete remissions in that patient population ranging from 20 -40%( with Rituxan). As both ADC's seem to be targeting the same diseases using different antigen targets, I wonder if getting no response from one potentially allows the patient to be a candidate for the other ADC.
That is a good question. I believe that patients are pre-screened for cd expression.
This is more than excellent news for SGEN. Adcetris + Rituxan represents a third drug targeting the same disease. The Roche testing is giving us a window into how well the SGEN trial may do. B cell is about 6bil market for Rituxan. SGEN may have a part of that entire market. While it may not be as lucrative as Rituxan, at the current price point B -cell represents an absolutely huge potential boost in future revenue.
This is only my worthless opinion.